p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy

被引：0
作者：
Ganly I. [1 ,2 ,3 ]
Soutar D.S. [1 ]
Brown R. [2 ]
Kaye S.B. [2 ]
机构：
[1] Dept. of Hd./Neck Plast./R., Canniesburn Hospital, Bearsden, Glasgow, Switchback Road
[2] CRC Dept. of Medical Oncology, Bearsden, Glasgow, Garscube Estate, Switchback Road
[3] CRC Dept. of Medical Oncology, CRC Beatson Laboratories, Glasgow G61 1BD, Garscube Estate, Switchback Road
来源：
British Journal of Cancer | 2000年 / 82卷 / 2期
关键词：
Head and neck cancer; HPV; Mdm2; p53;
D O I：
10.1054/bjoc.1999.0932
中图分类号：
学科分类号：
摘要：
The aim of the study was to determine the incidence of p53 alterations by mutation, deletion or inactivation by mdm2 or human papillomavirus (HPV) infection in recurrent squamous cell cancer of the head and neck (SCCHN) refractory to radiotherapy. Twenty-two tumours were studied. The p53 status of each tumour was analysed by sequencing of exons 4-9 and by immunohistochemistry. Mdm2 expression was assessed by immunohistochemistry and HPV infection was assessed by polymerase chain reaction of tumour DNA for HPV 16, 18 and 33. Fifteen (68%) of the 22 tumours studied had p53 mutations, while seven had wild-type p53 sequence. p53 immunohistochemistry correlated with the type of mutation. HPV DNA was detected in 8 (36%) tumours and all were of serotype HPV 16. Of these, five were in tumours with mutant p53 and three were in tumours with wild-type p53. Mdm2 overexpression was detected in 11 (50%) tumours. Of these, seven were in tumours with mutant p53 and four were in tumours with wild-type p53. Overall, 21 of the 22 tumours had p53 alterations either by mutation, deletion or inactivation by mdm2 or HPV. In this study, the overall incidence of p53 inactivation in recurrent head and neck cancer was very high at 95%. The main mechanism of inactivation was gene mutation or deletion which occurred in 15 of the 22 tumours studied. In addition, six of the seven tumours with wild-type p53 sequence had either HPV 16 DNA, overexpression of mdm2 or both which suggested that these tumours had p53 inactivation by these mechanisms. This high incidence of p53 dysfunction is one factor which could account for the poor response of these tumours to radiotherapy and chemotherapy. Therefore, new therapies for recurrent SCCHN which either act in a p53 independent pathway, or which restore p53 function may be beneficial in this disease.
引用
收藏
页码：392 / 398
页数：6
相关论文
共 48 条
[1]  
Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Et al., A mutant adenovirus which selectively replicates in tumour cells with nonfunctional p53, Science, 274, pp. 373-376, (1996)
[2]  
Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., Lane D.P., Design of a synthetic mdm2-binding mini protein that activates the p53 response in vivo, Curr Biol, 7, pp. 860-869, (1997)
[3]  
Boyle J.O., Koch W., Hruban R.H., Van Der Riet P., Sidransky D., The incidence of p53 mutations increases with progression of head and neck cancer, Cancer Res, 53, pp. 4477-4480, (1993)
[4]  
Brachman D.G., Graves D., Vokes E., Beckett M., Haraf D., Montag A., Et al., Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer, Cancer Res, 52, pp. 4832-4836, (1992)
[5]  
Buttitta F., Marchetti A., Gadducci A., Pellegrini S., Morganti M., Carnicelli V., Et al., p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study, Br J Cancer, 75, pp. 230-235, (1997)
[6]  
Catimel G., Verweij J., Mattijssen V., Hanauske A., Piccart M., Wanders J., Et al., Docetaxel (taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck, Ann Oncol, 5, pp. 533-537, (1994)
[7]  
Czegledy J., Iosif C., Hanson B.G., Evander M., Gergely L., Wadell G., Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastases in cervical cancer, Int J Cancer (Pred Oncol), 64, pp. 211-215, (1995)
[8]  
Chung K.Y., Mukhopadhyay T., Kim J., Casson A., Ro J.Y., Goepfert H., Et al., Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract, Cancer Res, 53, pp. 1676-1683, (1993)
[9]  
Clavel M., Vermorken J.B., Cognetti F., Cappelaere P., De Mulder P.H.M., Schornagel J.H., Et al., Randomised comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil versus cisplatin in recurrent or metastatic squamous cell carcinoma of head and neck, Ann Oncol, 5, pp. 521-526, (1994)
[10]  
Clayman G.L., El-Naggar A.K., Roth J.A., Zhang W.W., Goepfert H., Taylor D.L., Et al., In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma, Cancer Res, 55, pp. 1-6, (1995)
12345